No beneficial effects of resveratrol on the metabolic syndrome: A randomized placebo-controlled clinical trial

Journal of Clinical Endocrinology and Metabolism

Volumn 102, Issue 5, 2017, Pages 1642-1651

  Kjær, Thomas Nordstrøm ^a,b   Ornstrup, Marie Juul ^a,b   Poulsen, Morten Møller ^a,b   Stødkilde Jørgensen, Hans ^a,b   Jessen, Niels ^a   Jørgensen, Jens Otto Lunde ^a,b   Richelsen, Bjørn ^a,b   Pedersen, Steen Bønløkke ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; FRUCTOSAMINE; INTERLEUKIN 6; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MITOCHONDRIAL TRANSCRIPTION FACTOR A; PLACEBO; RESVERATROL; SIRTUIN 1; SOMATOMEDIN B; SOMATOMEDIN C; TRANSCRIPTION FACTOR NRF1; TUMOR NECROSIS FACTOR; UROKINASE RECEPTOR; ANTIOXIDANT; CHOLESTEROL; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IL6 PROTEIN, HUMAN; INSULIN; LEPTIN; STILBENE DERIVATIVE; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DEACETYLATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INFLAMMATION; INSULIN SENSITIVITY; INTRAPERITONEAL FAT; LIPID METABOLISM; LIPID STORAGE; LONG TERM CARE; MALE; METABOLIC SYNDROME X; MUSCLE BIOPSY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL; WAIST CIRCUMFERENCE; WESTERN BLOTTING; ADIPOSE TISSUE; BLOOD PRESSURE; DIAGNOSTIC IMAGING; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; INSULIN RESISTANCE; INTRAABDOMINAL FAT; LIVER; METABOLISM; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOTON ABSORPTIOMETRY; QUADRICEPS FEMORIS MUSCLE; REAL TIME POLYMERASE CHAIN REACTION; SKELETAL MUSCLE;

ABSORPTIOMETRY, PHOTON; ADIPOSE TISSUE; ANTIOXIDANTS; BLOOD GLUCOSE; BLOOD PRESSURE; BLOTTING, WESTERN; BODY COMPOSITION; C-REACTIVE PROTEIN; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; DOUBLE-BLIND METHOD; FRUCTOSAMINE; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LEPTIN; LIVER; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MUSCLE, SKELETAL; QUADRICEPS MUSCLE; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; STILBENES; TRIGLYCERIDES;

EID: 85014550884     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2160     Document Type: Article

References (34)

1. Dixon JB. The effect of obesity on health outcomes. Mol Cell Endocrinol. 2010;316(2):104-108.
2. Poulsen MM, Fjeldborg K, Ornstrup MJ, Kjær TN, Nøhr MK, Pedersen SB. Resveratrol and inflammation: Challenges in translatingpre-clinical findings to improved patient outcomes. Biochim Biophys Acta. 2015;1852(6):1124-1136.
3. Bitterman JL, Chung JH. Metabolic effects of resveratrol: Addressingthe controversies. Cell Mol Life Sci. 2015;72(8):1473-1488.
4. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrolimproves health and survival of mice on a high-calorie diet. Nature. 2006;444(7117):337-342.
5. Cullberg KB, Olholm J, Paulsen SK, Foldager CB, Lind M, Richelsen B, Pedersen SB. Resveratrol has inhibitory effects on thehypoxia-induced inflammation and angiogenesis in human adiposetissue in vitro. Eur J Pharm Sci. 2013;49(2):251-257.
6. Olholm J, Paulsen SK, Cullberg KB, Richelsen B, Pedersen SB. Antiinflammatoryeffect of resveratrol on adipokine expression andsecretion in human adipose tissue explants. Int J Obes (Lond. ). 2010;34(10):1546-1553.
7. Brasnyó P, Molná r GA, Mohá s M, Markó L, Laczy B, Cseh J, Mikolá s E, Szijá rtó IA, Mérei A, Halmai R, Mészá ros LG, SümegiB, Wittmann I. Resveratrol improves insulin sensitivity, reducesoxidative stress and activates the Akt pathway in type 2 diabeticpatients. Br J Nutr. 2011;106(3):383-389.
8. Timmers S, Konings E, Bilet L, Houtkooper RH, van de Weijer T, Goossens GH, Hoeks J, van der Krieken S, Ryu D, Kersten S, Moonen-Kornips E, Hesselink MK, Kunz I, Schrauwen-Hinderling VB, Blaak EE, Auwerx J, Schrauwen P. Calorie restriction-likeeffects of 30 days of resveratrol supplementation on energymetabolism and metabolic profile in obese humans. Cell Metab. 2011;14(5):612-622.
9. Poulsen MM, Vestergaard PF, Clasen BF, Radko Y, Christensen LP, Stodkilde-Jorgensen H, Moller N, Jessen N, Pedersen SB, Jorgensen JO. High-dose resveratrol supplementation in obesemen: An investigator-initiated, randomized, placebo-controlledclinical trial of substrate metabolism, insulin sensitivity, body composition. Diabetes. 2013;62(4):1186-1195.
10. Yoshino J, Conte C, Fontana L, Mittendorfer B, Imai S, Schechtman KB, Gu C, Kunz I, Rossi Fanelli F, Patterson BW, Klein S. Resveratrol supplementation does not improve metabolic functionin nonobese women with normal glucose tolerance. Cell Metab. 2012;16(5):658-664.
11. Tomé-Carneiro J, Gonzá lvez M, Larrosa M, Yán~ez-Gascó n MJ, Garcá-Almagro FJ, Ruiz-Ros JA, Toḿ as-Barberán FA, Garcá-Conesa MT, Esṕn JC. Grape resveratrol increases serum adiponectinand downregulates inflammatory genes in peripheral bloodmononuclear cells: A triple-blind, placebo-controlled, one-yearclinical trial in patients with stable coronary artery disease. Cardiovasc Drugs Ther. 2013;27(1):37-48.
12. Magyar K, Halmosi R, Palfi A, Feher G, Czopf L, Fulop A, Battyany I, Sumegi B, Toth K, Szabados E. Cardioprotection by resveratrol:a human clinical trial in patients with stable coronary artery disease. Clin Hemorheol Microcirc. 2012;50(3):179-187.
13. Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, Franklin M, Klein K, Taylor PJ, Ferguson M, Coombes JS, Thomas GP, Cowin GJ, Kirkpatrick CM, Prins JB, Hickman IJ. Resveratrol does not benefit patients with nonalcoholicfatty liver disease. Clin Gastroenterol Hepatol. 2014;12(12):2092-103. e1-6.
14. Mc Anulty LS, Miller LE, Hosick PA, Utter AC, Quindry JC, Mc Anulty SR. Effect of resveratrol and quercetin supplementationon redox status and inflammation after exercise. Appl Physiol Nutr Metab. 2013;38(7):760-765.
15. Bakker GC, van Erk MJ, Pellis L, Wopereis S, Rubingh CM, Cnubben NH, Kooistra T, van Ommen B, Hendriks HF. Anantiinflammatory dietary mix modulates inflammation and oxidativeand metabolic stress in overweight men: A nutrigenomicsapproach. Am J Clin Nutr. 2010;91(4):1044-1059.
16. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome-a new worldwidedefinition. A consensus statement from the International Diabetes Federation. Diabet Med. 2006;23(5):469-480.
17. Kjaer TN, Ornstrup MJ, Poulsen MM, Jørgensen JO, Hougaard DM, Cohen AS, Neghabat S, Richelsen B, Pedersen SB. Resveratrolreduces the levels of circulating androgen precursors but has noeffect on, testosterone, dihydrotestosterone, PSA levels or prostatevolume. A 4-month randomised trial in middle-aged men. Prostate. 2015;75(12):1255-1263.
18. Ornstrup MJ, Harsløf T, Kjær TN, Langdahl BL, Pedersen SB. Resveratrol increases bone mineral density and bone alkalinephosphatase in obese men: A randomized placebo-controlled trial. J Clin Endocrinol Metab. 2014;99(12):4720-4729.
19. Wamberg L, Kampmann U, Stødkilde-Jørgensen H, Rejnmark L, Pedersen SB, Richelsen B. Effects of vitamin D supplementation onbody fat accumulation, inflammation, metabolic risk factors inobese adults with low vitamin D levels-results from a randomizedtrial. Eur J Intern Med. 2013;24(7):644-649.
20. Positano V, Gastaldelli A, Sironi AM, Santarelli MF, Lombardi M, Landini L. An accurate and robust method for unsupervised assessmentof abdominal fat by MRI. J Magn Reson Imaging. 2004;20(4):684-689.
21. Provencher SW. Estimation of metabolite concentrations fromlocalized in vivo proton NMR spectra. Magn Reson Med. 1993;30(6):672-679.
22. Moller AB, Vendelbo MH, Christensen B, Clasen BF, Bak AM, Jorgensen JO, Moller N, Jessen N. Physical exercise increasesautophagic signaling through ULK1 in human skeletal muscle. JAppl Physiol (1985). 2015;118(8):971-979.
23. Gü rtler A, Kunz N, Gomolka M, Hornhardt S, Friedl AA, Mc Donald K, Kohn JE, Posch A. Stain-Free technology as a normalizationtool in Western blot analysis. Anal Biochem. 2013;433(2):105-111.
24. Inoue H, Nakata R. Resveratrol targets in inflammation. Endocr Metab Immune Disord Drug Targets. 2015;15(3):186-195.
25. Szkudelski T, Szkudelska K. Resveratrol and diabetes: From animalto human studies. Biochim Biophys Acta. 2015;1852(6):1145-1154.
26. Faghihzadeh F, Hekmatdoost A, Adibi P. Resveratrol and liver:a systematic review. J Res Med Sci. 2015;20(8):797-810.
27. Singh CK, Ndiaye MA, Ahmad N. Resveratrol and cancer: Challengesfor clinical translation. Biochim Biophys Acta. 2015;1852(6):1178-1185.
28. Sung MM, Dyck JR. Therapeutic potential of resveratrol in heartfailure. Ann N Y Acad Sci. 2015;1348(1):32-45.
29. Poulsen MM, Jørgensen JO, Jessen N, Richelsen B, Pedersen SB. Resveratrol in metabolic health: An overview of the current evidenceand perspectives. Ann N Y Acad Sci. 2013;1290(1):74-82.
30. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, Vasilinin G, Sen A, Schinas AM, Piccirilli G, Brown K, Steward WP, Gescher AJ, Brenner DE. Repeat dose study of the cancerchemopreventive agent resveratrol in healthy volunteers: Safety, pharmacokinetics, effect on the insulin-like growth factor axis. Cancer Res. 2010;70(22):9003-9011.
31. Thazhath SS, Wu T, Bound MJ, Checklin HL, Standfield S, Jones KL, Horowitz M, Rayner CK. Administration of resveratrol for5 wk has no effect on glucagon-like peptide 1 secretion, gastricemptying, or glycemic control in type 2 diabetes: A randomizedcontrolled trial. Am J Clin Nutr. 2016;103(1):66-70.
32. Youssef D, El Abbassi A, Jordan RM, Peiris AN. Fructosamine-anunderutilized tool in diabetes management: Case report and literaturereview. Tenn Med. 2008;101(11):31-33.
33. Malmström H, Walldius G, Grill V, Jungner I, Gudbjö rnsdottir S, Hammar N. Fructosamine is a useful indicator of hyperglycaemiaand glucose control in clinical and epidemiological studies-crosssectionaland longitudinal experience from the AMORIS cohort. PLOS One. 2014;9(10):e111463.
34. Poulsen MM, Ornstrup MJ, Harslof T, Jessen N, Langdahl BL, Richelsen B, Jorgensen JO, Pedersen SB. Short-term resveratrolsupplementation stimulates serum levels of bone-specific alkalinephosphatase in obese non-diabetic men. J Funct Foods. 2014;6:305-310.